Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00007910
DRKS00007910
Recruiting
Phase 2

Augmentation of Interpersonal Psychotherapy (IPT) with D-cycloserine - NeuroIPT-1

niversitätsklinikum Freiburg; Sponsordelegation an Prof. Dr. Claus Normann0 sites28 target enrollmentJune 9, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsF32.2F33.2Severe depressive episode without psychotic symptomsRecurrent depressive disorder, current episode severe without psychotic symptoms

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
F32.2
Sponsor
niversitätsklinikum Freiburg; Sponsordelegation an Prof. Dr. Claus Normann
Enrollment
28
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 9, 2016
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversitätsklinikum Freiburg; Sponsordelegation an Prof. Dr. Claus Normann

Eligibility Criteria

Inclusion Criteria

  • •Major depressive disorder (ICD\-10: F32\.2 and F33\.2\)
  • •\- Inpatients at the Department of Psychiatry and Psychotherapy, Freiburg
  • •\- Score of \=15 and \= 45 on the 21\-item Hamilton Rating Scale for Depression (HAMD)
  • •\- 20\-60 years of age
  • •\- Ability to provide informed consent
  • •\- Absence of any exclusion criteria

Exclusion Criteria

  • •Hypersensitivity to D\-cycloserine
  • •\- Neurological disorders including epilepsy, history of brain injury, encephalitis, or any organic brain syndrome
  • •\- Metallic implants
  • •\- Present pregnancy
  • •\- DSM\-V axis I disorder (lifetime) apart from major depression, such as schizophrenia, schizoaffective disorder, any non\-bipolar psychotic disorder, bipolar disorders, primary anxiety or obsessive compulsive disorder, mental retardation, signs of impaired cognitive functioning
  • •\- Acute suicidality
  • •\- Psychotic features of MDD
  • •\- Lifetime history for drug/alcohol dependence, or drug/alcohol abuse within the past year \- Antidepressive pharmacotherapy other than monotherapy with SSRI, bupropion or venlafaxine
  • •\- Medical conditions including severe cardiac, liver, kidney, endocrine (e.g., diabetes), hematologic disorders (e.g., porphyria or any bleeding abnormalities), other impairing or unstable medical condition or impending surgery
  • •\- Inability to read or understand the study forms and agree to informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
euroenhancement of Interpersonal Psychotherapy in Major DepressioMajor Depression (ICD-10F32.2/F33.2)Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2014-001541-24-DEniversity Medical Center Freiburg
Recruiting
Phase 1
The Parent Transition ProgramDepression and Interpersonal problems (loss & grief, interpersonal disputes, social isolation, role transitions).Mental Health - Depression
ACTRN12606000393550Gold Coast Community Child Health120
Completed
Not Applicable
Effect of Interpersonal Psychotherapy in Depressed WomeMDD.Major depressive disorder, recurrent
IRCT20210706051804N1Islamic Azad University30
Active, not recruiting
Not Applicable
A randomised control trial assessing the effects of Group Interpersonal Therapy (IPT-g) on depressioDepressionMental and Behavioural Disorders
ISRCTN15091477Hudara gGmbH160
Completed
Phase 4
Interpersonal Psychotherapy for Groups adapted for the Ugandan Population: A randomized controlled trial of six sessions versus eight sessions of trigger concordant and trigger discordant therapyMental and Behavioural Disorders
PACTR202306771120632StrongMinds300